GlassScriptPhysician profile
Kenneth S Weiss
NPI 1225087877
$5,005.60
in general payments reported to CMS, 2019-2025
31 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $91.35 · 2021: $228 · 2022: $276 · 2023: $765 · 2024: $1,363 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,708.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $923.13 | 2019-2025 | Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $529.96 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $454.62 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Gilead Sciences, INC. | $367.42 | 2019-2025 | |
| Abbott Laboratories | $362.06 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $337.60 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.96 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $278.43 | 2021-2025 | |
| Astellas Pharma US INC | $272.09 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $178.25 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $132.82 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $85.12 | 2019-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.90 | 2019 | |
| Theratechnologies INC. | $81.90 | 2024 | Egrifta Sv |
| Intra-Sana Laboratories | $69.31 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $63.36 | 2023-2025 | Inspire |
| Dexcom, INC. | $61.56 | 2021-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $51.41 | 2022 | |
| Bausch Health US, LLC | $45.96 | 2025 | Wellbutrin |
| Merck Sharp & Dohme LLC | $44.71 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $43.98 | 2019-2020 | |
| Dynavax Technologies Corporation | $37.82 | 2022-2023 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $35.74 | 2021 | |
| Sanofi Pasteur INC. | $30.29 | 2019-2020 | |
| Allergan, INC. | $28.94 | 2019-2020 | |
| Viiv Healthcare Company | $24.15 | 2025 | Apretude |
| Janssen Biotech, INC. | $19.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.56 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.32 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.68 | 2024 | Crysvita |
| Horizon Therapeutics Plc | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.